Impact of prostate volume on the active surveillance in prostate cancer

被引:0
|
作者
Beaujouan, Florent [1 ]
Bertherat, Walter [2 ]
Hammoudi, Zakaria [1 ]
Chicaud, Marie [1 ]
Descazeaud, Aurelien [1 ]
机构
[1] Univ Hosp Ctr Dupuytren, Dept Urol Surg & Androl, 16 rue Petiniaud-Beaupeyrat, F-87000 Limoges, France
[2] Perigueux Hosp Ctr, Dept Urol Surg & Androl, Perigueux, France
关键词
Prostatic neoplasms; active surveillance; prostate-specific antigen; prostatic hyperplasia; prognostic factors; FOLLOW-UP; ANTIGEN KINETICS; GUIDELINES; MANAGEMENT; DIAGNOSIS; OUTCOMES; PREDICT; UPDATE; BIOPSY; COHORT;
D O I
10.1177/20514158241303972
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the influence of the prostate volume (PVo) in the management of patients in active surveillance (AS) for prostate cancer. Materials and methods: A retrospective analysis of clinical, biological, histological and radiological data collected between 2010 and 2021 was performed for patients included in an AS protocol in a university hospital. The impact of initial PVo on the subsequent risk of exiting AS was evaluated. Results: In total, 109 patients were included in this analysis with a mean follow-up period of 52.74 +/- 31 months, 50% were out of AS by the end of the follow-up period. The risk of exiting the AS protocol was significantly associated to the PVo: patients with smaller PVo had an increased risk of exiting AS (p = 0.025). The maximal percentage of core invasion was the only initial predictive parameter for exiting the AS protocol on multivariate analysis of the global cohort (p = 0.010) and in the sub-group of patients having PVo <= 45 mL (p = 0.013). In the group having a PVo > 45 mL, no single initial parameter was significantly associated to a risk of exiting AS. Conclusion: Patients having small-sized prostate seemed to be at higher risk of exiting AS during follow-up.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Identifying intermediate-risk candidates for active surveillance of prostate cancer
    Savdie, Richard
    Aning, Jonathan
    So, Alan I.
    Black, Peter C.
    Gleave, Martin E.
    Goldenberg, S. Larry
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) : 605.e1 - 605.e8
  • [32] Active Surveillance for Prostate Cancer: A Systematic Review of the Literature
    Dall'Era, Marc A.
    Albertsen, Peter C.
    Bangma, Christopher
    Carroll, Peter R.
    Carter, H. Ballentine
    Cooperberg, Matthew R.
    Freedland, Stephen J.
    Klotz, Laurence H.
    Parker, Christopher
    Soloway, Mark S.
    EUROPEAN UROLOGY, 2012, 62 (06) : 976 - 983
  • [33] Active surveillance in intermediate risk prostate cancer: is it safe?
    Krishnananthan, Nishanth
    Lawrentschuk, Nathan
    INTERNATIONAL BRAZ J UROL, 2016, 42 (03): : 418 - 421
  • [34] Active surveillance for intermediate-risk prostate cancer
    Nayan, Madhur
    Carvalho, Filipe L. F.
    Feldman, Adam S.
    WORLD JOURNAL OF UROLOGY, 2022, 40 (01) : 79 - 86
  • [35] Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach
    Lee, Chau Hung
    Tan, Teck Wei
    Tan, Cher Heng
    KOREAN JOURNAL OF RADIOLOGY, 2021, 22 (07) : 1087 - 1099
  • [36] Active surveillance for prostate cancer: past, present and future
    Singer, Eric A.
    Kaushal, Aradhana
    Turkbey, Baris
    Couvillon, Anna
    Pinto, Peter A.
    Parnes, Howard L.
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 243 - 250
  • [37] The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance
    Monfared, Sina
    Fleishman, Aaron
    Korets, Ruslan
    Chang, Peter
    Wagner, Andrew
    Bubley, Glenn
    Kaplan, Irving
    Olumi, Aria F.
    Gershman, Boris
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (11) : 783.e21 - 783.e30
  • [38] Active surveillance for low-risk prostate cancer
    Bangma, Chris H.
    Bul, Meelan
    van der Kwast, Theo H.
    Pickles, Tom
    Korfage, Ida J.
    Hoeks, Caroline M.
    Steyerberg, Ewout W.
    Jenster, Guido
    Kattan, Michael W.
    Bellardita, Lara
    Carroll, Peter R.
    Denis, Louis J.
    Parker, Chris
    Roobol, Monique J.
    Emberton, Mark
    Klotz, Laurence H.
    Rannikko, Antti
    Kakehi, Yoshiyuki
    Lane, Janet A.
    Schroder, Fritz H.
    Semjonow, Axel
    Trock, Bruce J.
    Valdagni, Riccardo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) : 295 - 302
  • [39] Medium-term Outcomes of Active Surveillance for Localised Prostate Cancer
    Selvadurai, Elizabeth D.
    Singhera, Mausam
    Thomas, Karen
    Mohammed, Kabir
    Woode-Amissah, Ruth
    Horwich, Alan
    Huddart, Robert A.
    Dearnaley, David P.
    Parker, Chris C.
    EUROPEAN UROLOGY, 2013, 64 (06) : 981 - 987
  • [40] Active surveillance in prostate cancer
    Erne, E.
    Kaufmann, S.
    Nikolaou, K.
    Stenzl, A.
    Bedke, J.
    UROLOGE, 2019, 58 (05): : 511 - 517